#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2492	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1909	237.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1616	1616	T	212	T,C	117,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2492	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1909	237.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1350	1350	C	292	C	172	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2492	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1909	237.7	0	HET	.	.	.	C411T	.	411	411	C	577	577	C	222	C,T	101,32	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4314	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3586	209.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1813	1813	A	201	A	132	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4314	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3586	209.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2447	2447	C	164	C	96	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4314	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3586	209.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3073	3073	T	211	T	129	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4314	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3586	209.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2521	2521	A	171	A	101	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	170	folP	855	855	100.0	folP.l15.c4.ctg.1	1259	25.6	1	SNP	p	R229S	1	.	.	685	687	AGC	828	830	AGC	46;46;46	A;G;C	28;28;27	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	438	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3274	24.2	1	SNP	p	S91F	1	.	.	271	273	TTC	581	583	TTC	21;21;21	T;T;C	11;11;12	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	438	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3274	24.2	1	SNP	p	D95G	1	.	.	283	285	GGC	593	595	GGC	24;24;24	G;G;C	14;14;13	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	438	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3274	24.2	1	SNP	p	G95N	0	.	.	283	285	GGC	593	595	GGC	24;24;24	G;G;C	14;14;13	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	112	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1059	20.0	1	SNP	p	G45D	0	.	.	133	135	GGC	387	389	GGC	25;25;25	G;G;C	14;15;16	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	68	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	655	16.0	0	.	n	.	0	A197.	DEL	197	197	A	272	272	A	26	A	15	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2639	25.3	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1339	1341	GTC	21;21;21	G;T;C	15;14;15	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2639	25.3	1	SNP	p	D86N	0	.	.	256	258	GAC	445	447	GAC	38;38;39	G;A;C	21;21;20	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2639	25.3	1	SNP	p	R87I	0	.	.	259	261	CGT	448	450	CGT	39;39;40	C;G;T	24;20;19	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2639	25.3	1	SNP	p	S87R	1	.	.	259	261	CGT	448	450	CGT	39;39;40	C;G;T	24;20;19	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2639	25.3	1	SNP	p	R87W	0	.	.	259	261	CGT	448	450	CGT	39;39;40	C;G;T	24;20;19	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2639	25.3	1	SNP	p	S88P	0	.	.	262	264	TCC	451	453	TCC	40;40;40	T;C;C	23;23;23	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	268	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2974	16.2	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1539	1541	TGC	37;37;35	T;G;C	20;18;16	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	268	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2974	16.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1749	1751	GGC	14;15;16	G;G;C	9;10;9	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1192	1194	GCA	57;59;59	G;C;A	30;33;32	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1195	1197	ATC	59;59;59	A;T;C	34;33;32	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1207	1209	GTG	58;58;58	G;T;G	33;32;31	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1207	1209	GTG	58;58;58	G;T;G	33;32;31	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1711	1713	ACC	29;29;28	A;C;C	16;19;19	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1765	1767	GCG	20;20;20	G;C;G	11;9;10	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1765	1767	GCG	20;20;20	G;C;G	11;9;10	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1888	1890	GGC	9;9;10	G;G;C	6;7;9	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1897	1899	GGC	9;8;7	G;G;C	8;7;5	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	380	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2213	29.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1915	1917	TCG	9;9;9	T,G;C;G	5,1;6;3	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	844	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3263	44.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1730	1732	CCG	18;18;18	C;C;G	10;12;11	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	204	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1867	19.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	628	628	C	25	C	15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	519	521	TTA	4;4;4	T;T;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	564	566	CAT	4;2;2	C;A;T	2;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	567	569	AGT	2;2;2	A;G;T	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	576	578	TAC	2;2;2	T;A;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	R307A	NONSYN	919	921	AGA	666	668	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	678	680	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	681	683	GAC	1;1;1	G;A;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	687	689	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	693	695	TCG	1;1;1	T;C;G	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	699	701	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	702	704	AGC	1;1;1	A;G;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	705	707	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	14	porB1a	984	270	91.48	porB1a.l6.c4.ctg.1	748	1.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	711	713	GTT	1;1;1	G;T;T	1;1;1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	474	476	GAA	32;32;33	G;A;A	22;22;22	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	762	764	GAT	34;39;40	G;A;T	22;22;24	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	885	887	TCA	51;51;52	T;C;A	31;28;32	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1014	1016	GTC	38;39;39	G,A;T;C	22,1;25;23	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1344	1346	GCA	31;31;31	G;C;A	19;19;18	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	1	SNP	p	G120K	1	.	.	358	360	AAG	720	722	AAG	35;35;37	A;A;G	22;19;21	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	1	SNP	p	D121N	0	.	.	361	363	GAC	723	725	GAC	37;37;37	G;A;C	21;21;22	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	252	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1707	27.4	1	SNP	p	A121D	1	.	.	361	363	GAC	723	725	GAC	37;37;37	G;A;C	21;21;22	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1150	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4860	43.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2075	2077	AAT	34;34;34	A;A;T	21;22;21	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	90	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	896	18.9	1	SNP	p	V57M	1	.	.	169	171	ATG	441	443	ATG	25;25;25	A;T;G	15;16;15	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
